The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
Jonathan E Dowell and John D Minna*
Correspondence *Hamon Center for Therapeutic Oncology Research NB8.206, University of Texas, Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
Email john.minna@utsouthwestern.edu
Non-small-cell lung cancer is the leading cause of cancer death in the US despite advances in therapy. The epidermal-growth-factor receptor has been investigated as a target for therapy using EGFR-specific tyrosine kinase inhibitors. This Viewpoint discusses the implications of the correlation of positive responses seen in patients harboring EGFR mutations.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cancer Broken genes in solid tumoursNature News and Views (02 Aug 2007)
Selecting the right patient for tumor therapyNature Medicine News and Views (01 Jun 2004)